Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
i.v. recombinant human C1 inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Recombinant Human C1INH | EXPERIMENTAL | - |
| 1 | OTHER | Open-label i.v. administration of 100 U/kg rhC1INH |
| Name | Type | Description |
|---|---|---|
| i.v. recombinant human C1 inhibitor | DRUG | - |
Main inclusion Criteria: * Clinical and laboratory diagnosis of HAE * Plasma level of functional C1INH of less than 50% of normal * Severe attack of abdominal, facial-oro-pharyngeal, genito-urinary and/or peripheral HAE. Main exclusion Criteria: * Acquired angioedema * Pregnancy or breastfeeding ...
I.v. recombinant human C1 inhibitor is an investigational therapy being studied for the treatment of acute attacks in patients with hereditary angioedema, a genetic disorder. It is administered intravenously and is currently in Phase 2 clinical development.
I.v. recombinant human C1 inhibitor is being developed by Pharming Group N.V., a biopharmaceutical company listed on the stock exchange under the ticker symbol PHAR.
I.v. recombinant human C1 inhibitor is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, but the drug remains in clinical development.
I.v. recombinant human C1 inhibitor has been studied in two completed Phase 2 clinical trials: NCT00261053 and NCT00262288. Both trials evaluated the drug for the treatment of acute attacks in patients with hereditary angioedema and were conducted in the Netherlands.
I.v. recombinant human C1 inhibitor is a recombinant form of the human C1 inhibitor protein. It is designed to replace the deficient or dysfunctional C1 inhibitor in patients with hereditary angioedema, thereby helping to control acute attacks of the condition.